Skip to main content
Hajj And Omrah
About SFDA
About SFDA
نظرة عامة
Authority Establishment
Authority Membership
Authority Activities
Authority Management
Board of directors
SFDA in vision 2030
Vision Realization Office
National Transformation Program
Health Sector Transformation Program
National Industrial Development and Logistics Program
Authority Strategy
Strategy
Authority Values
Annual Reports
Career and Life
Life in SFDA
Career General Goals
Information Lists
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Areas
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Evaluation Program
Decisions
نظرة عامة
Laws and Regulations
Guidelines
Drugs Circulars
forms
Circulars
FAQ
Sector Committee
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Studies and Research
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
Forms
Circulars
FAQ
نظرة عامة
Scientific reports and statements
Laws and Regulations
Guidelines
Consumer Corner
Awareness Campaign
Topics of Interest
Interactive calculators
Media Centre
News
Rumours
Warnings
Events
Workshops
ميديا
Podcasts
Forms
Scientific Magazines And Articles
Eservices
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Font Resize
+A
A
-A
Contrast
عربي
Hajj And Omrah
About SFDA
About SFDA
نظرة عامة
Authority Establishment
Authority Membership
Authority Activities
Authority Management
Board of directors
SFDA in vision 2030
Vision Realization Office
National Transformation Program
Health Sector Transformation Program
National Industrial Development and Logistics Program
Authority Strategy
Strategy
Authority Values
Annual Reports
Career and Life
Life in SFDA
Career General Goals
Information Lists
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Areas
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Evaluation Program
Decisions
نظرة عامة
Laws and Regulations
Guidelines
Drugs Circulars
forms
Circulars
FAQ
Sector Committee
نظرة عامة
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Studies and Research
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
Laws and Regulations
Guidelines
forms
Circulars
FAQ
نظرة عامة
Laws and Regulations
Guidelines
Forms
Circulars
FAQ
نظرة عامة
Scientific reports and statements
Laws and Regulations
Guidelines
Consumer Corner
Awareness Campaign
Topics of Interest
Interactive calculators
Media Centre
News
Rumours
Warnings
Events
Workshops
ميديا
Podcasts
Forms
Scientific Magazines And Articles
Eservices
All
The Authority
Food
Drugs
Medical Devices
الأعلاف
Pesticides
Laboratories
Cosmetics
Tobacco
Halal
Nutrition
Home
Search Results
Containing any of the words
Only of the type
All
Conference
hpac-members
Periodic Safety
test
calculators
Cosmetics standards Project
Cosmetics Warning
covid pages
Drug evaluation reports
Drug Membership
Events
Hajj card
List Drugs Withdrawal
Marketed Products
Open Data
Podcasts
portables service
Regulations exceptions
Safety Alert
Scientific reports and statement
sector committee
service providing facilities
Speakers
Vaccine Safety
Annual Report
Awareness Article
Awareness Campaign
Circulars
Clinical Trial
Drug Clinical Trial
Drug Log
Drug Safety Labeling
Eservices
Event
Excellent establishments list
Forms
HAPC Committee Decisions
head of board
Information List
International Standard
Laboratories
Lists
List of hospital that reported sides effects
List Registered Drugs
List Registered Pharmacies
List Shortage Drug
List Under registration Drugs / Under committee review
Medical devices studies
Medical Report
Message
News
New SFDA Drug Approvals
Reference repositories drugs
Risk Minimization Activity
Risk Minimization Activity - New
Rumours
Scientific Magazines and articles
Sector Committee decisions
Standard
Standards Projects For Medical Devices
Surveys
Warehouse
Warnings
A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
Drug Clinical Trial
An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
Drug Clinical Trial
An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma (EVERMORE).
Drug Clinical Trial
A 24 month, randomized, controlled, study to evalute the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus in recipients of living donor liver transplants.
Drug Clinical Trial
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4
Drug Clinical Trial
A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy
Drug Clinical Trial
"An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction"
Drug Clinical Trial
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'
Drug Clinical Trial
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)
Drug Clinical Trial
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Drug Clinical Trial
Pagination
First page
« First
Previous page
‹ Previous
…
الصفحة
510
الصفحة
511
الصفحة
512
الصفحة
513
Current page
514
الصفحة
515
الصفحة
516
الصفحة
517
الصفحة
518
…
Next page
Next ›
Last page
Last »